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Abstract 
A mammalian homolog of Drosophila Grainyhead 
protein, Grainyhead like 2 belongs to the Grainy 
Head-Like Proteins/CCAAT binding protein, 
GRH/CP2 family which is conserved from 
drosophila to mammals (Venkatesan, 2003).  In 
mammals, there are 3 members of the family, 
GRHL1-3, the expression of which exhibit 
differential spatiotemporal expression patterns 
during development and in adult tissues. The GRHL 
family members are essential developmental 
transcription factors in epithelial cell 
morphogenesis/differentiation and in tumorigenesis 
(Stramer and Martin, 2005; Werth et al., 2010). 
Although the family members have common 
molecular and biological functions during 
development, they rarely exhibit functional 
redundancy due to different gene targets (Boglev et 
al., 2011).  GRHL2 can act as a tumor-suppressor or 
oncogene depending upon tissue of expression. 
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Identity 
Other names 
Transcription Factor CP2-Like 3 (TFCP2L3) 
Brother Of Mammalian Grainyhead (BOM) 
Grainyhead-Like Protein 2 Homolog Deafness 
Autosomal Dominant 28 
HGNC (Hugo) 
GRHL2 
Location 
8q22.3 
Location (base pair) 
Starts at 101,492,440 and ends at 101,669,726 bp 
(GRCh38:CM000670.2) ; + strand 
Orange arrow indicates the GRHL2 (NC_000008.11) location on chromosome 8 on positive strand shown as 
black line. Green arrow indicates NCALD, the closest gene to GRHL2. 
DNA/RNA 
Note 
The GRHL2 located on chromosome 8q22.3 is on 
the forward strand and spans 177287 bp on the  
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genome. It has 16 exons. The primary mRNA 
transcript 1 (NM_024915.3) is 5231 bp in length and 
contains an open reading frame of 1878 bp (NCBI 
,2017). 
 
Exons are shown in boxes; lines indicate introns. The encoding exons are in green. The start codon ATG and 
stop codon TGA are shown. 
Description 
The human GRHL2 gene is located on chromosome 
8 and contains 16 exons. 
Transcription 
It appears that an internal 5' splicing site within the 
first exon of GRHL2 generates an alternate GRHL2 
mRNA (NM_001330593) with a 203-base deletion 
containing the first Met encoding AUG codon in its 
5'-end. This results in the utilization of the second 
AUG within exon 2 giving rise to an amino-
terminally truncated (16 residues) GRHL2 isoform 
(NP_001317522.1), GRHL2v (17-625) that displays 
a disrupted transactivation function. 
Protein 
Note 
GRHL2 variant 1 transcript encodes a 625 amino 
acids (aa) long protein (NP_079191.2). Based on 
GHRL2 and its Drosophila homolog GRH, the 
protein isoform 1 contains transcription activation 
domain at the amino-terminus (1-93 aa) and a large 
CP2 Transcription Factor domain between 119-438 
aa that is responsible for DNA binding as well as a 
dimerization domain at the carboxyl-terminus 
(Attardi and Tijan, 1993, Kokoszynska et al., 2017; 
Uv, Thompson and Bray, 1994). Resulting from the 
alternative splicing of GHRL2 transcript, GRHL2 
isoform 2 lacks the first 16 amino-acids and is a 609 
aa long protein (NP_001317522.1). GRHL2 isoform 
is reported to counteract the oncogenic potential of 
GRHL2 isoform 1 by acting as a dominant negative 
manner (Werner et al., 2013). 
Proteomic analyses also suggest that GRHL2 is a 
phosphoprotein in various normal and cancerous 
tissues as well as in cell lines (Mertins et al., 2016). 
 
GRHL2, composed of 625 aa, contains a transactivation domain between 1-93 aa; a CP2 domain between 119-
438 aa responsible for DNA binding and a dimerization/oligomerization domain at the carboxyl-terminus. 
 
Description 
GRHL2 protein is a transcription regulator that has a 
conserved CP2 domain. 
Expression 
In human adults, GRHL2 is expressed in the 
placenta, brain, kidney, prostate, thymus, lung, 
salivary gland, mammary gland, digestive tract, and  
 
pancreas (Wilanowski et al., 2002; Peters et al., 
2002). 
It is also reported that MIR194 and MIR217 inhibit 
the cellular proliferation and promote cellular 
differentiation by targeting the GRHL2 translation 
(Yu et al., 2017; Zhu et al.,2016). 
Localisation 
GRHL2 is localized primarily in the nucleus (Chen 
et al., 2010; Petrof et al., 2014). GRHL2 is also 
observed to be localized in the cytoplasm and at the 
inner cell membrane (Petrof et al., 2014). 
Function 
GRHL2 is a transcription factor. The GRHL2 
encodes a 71 kDa protein functions as DNA binding 
protein that interacts with permutations of the 
consensus sequence 5'-AACCGGTT-3' (Werner et 
al., 2013). GRHL2 appears to act as transcription 
repressor and/or activator depending on chromatin 
context of target genes (Mehrazarin.et al., 2015). 
Observations with experimental animal models 
indicate that the knock-out of, or nonsense mutations 
in, the mouse Grhl2 gene results in embryonic 
lethality due to defects in neural tube closure, 
epithelial morphogenesis, and barrier formation by 
de-regulation of cell junction protein expressions 
(Werth et al.,2010; Pyrgaki, Liu and Niswander, 
2011). This finding emphasizes the essentiality of 
Grhl2 for epithelial and neural morphogenesis 
during embryogenesis. 
GRHL2 is also implicated in the carcinogenesis of 
various tissues and organs. Consistent with its role in 
epithelial morphogenesis, GRHL2 is shown act as 
tumor-suppressor by controlling the epithelial-
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mesenchymal transition (EMT), an essential 
characteristic of tumor progression (Wellner et al., 
2009). In contrast, GRHL2 is also reported to act as 
an oncogene by promoting cell proliferation and 
survival (Cieply et al., 2013). Although underlying 
reasons are yet unclear, de-regulation of tissue/organ 
specific expression of the GHRL2 gene together 
with tissue/organ specific gene targets of GHRL2 is 
suggested to underlie the dual effects of GRHL2 on 
carcinogenesis (Wellner et al., 2009). 
Homology 
GRHL2 is a conserved gene among vertebrates and 
in Drosophila. 
Mutations 
Note 
Tyr to His substitution at the position 398 and Ile to 
Lys at 498 of GHRL2 are observed in ectodermal 
dysplasia (Petrof et al., 2014). In addition, single 
nucleotide insertion at the position 1609 is reported 
to lead to frame shift and early stop codon in the 
encoding transcript (Peters et al., 2002). 
Germinal 
Haploinsufficiency for GRHL2 implicated in non-
syndromic sensorineural deafness- autosomal 
dominant type 28 (DFNA28), due to frameshift 
mutations and single nucleotide polymorphism in the 
gene (Van Laer et al., 2007), are associated with 
hearing loss. (Peters et al., 2002). These variations in 
the GRHL2 gene are suggested to likely result in 
deregulated gene expressions encoding for cell 
junction proteins and ion channels in the otic 
epithelial cells, which are important for the inner ear 
development and homeostasis (Han et al., 2011).  
 
It is also reported that mutations in the GRHL2 
sequences encoding DNA binding domain result in 
an autosomal-recessive ectodermal Dysplasia 
syndrome (Petrof et al., 2014). 
Implicated in 
Breast cancer 
GRHL2 is implicated to play a role in epithelial-
mesenchymal transition (EMT) of breast cancer. It 
appears that increased expression of GHRL2 is 
inversely correlated with increased tumor stages and 
the presence of lymph node metastases (Cieply et al., 
2012).  Extending these observations, experimental 
studies using breast cancer cell models further 
suggest that the expression of GRHL2 is 
downregulated specifically in the claudin-low 
subclass breast tumors and in basal-B subclass breast 
cancer cell lines, where it suppresses EMT, enhances 
anoikis sensitivity, and suppresses mammosphere 
generation. Moreover, it appears that the GRHL2 
expression prevents tumor initiation in xenograft 
animal models and suppresses the emergence of 
phenotype indicative of cancer stem cell (Cieply et 
al.,2012). 
Esophageal cancer 
Studies suggest that de-regulated expression of the 
GRHL2 gene is common in esophageal cancer.  The 
expression of GRHL2 is observed to be higher in 
esophageal tumor tissue than that of in adjacent 
tissues (Shao et al., 2017).  The level of GRHL2 
expression appears also to be associated with tumor 
differentiation and to show correlation with lymph 
node metastasis and invasion depth. 
Gastric cancer 
GRHL2 is suggested to be a tumor suppressor in 
gastric tissue. The GRHL2 expression and GRHL2 
synthesis is reported to be reduced in gastric cancer 
compared to normal gastric tissues; it is therefore 
suggested that the down regulation of the GRHL2 
expression contributes tumor invasion and 
metastasis (Xiang et al., 2008). Consistent with this, 
the GRHL2 overexpression appears to inhibit the 
invasion and migration of cell models derived from 
gastric cancer (Xiang et al., 2017). 
Prostate cancer 
Based on gene expressions analyses, the GRHL2 
expression is observed to be upregulated in prostate 
cancer (Paltoglou et al., 2017; Danila et al., 2014). 
Kidney cancer 
Based on publically available data sets of 593 clear 
cell renal cell carcinoma (ccRCC) and 389 normal 
kidney samples and verification with patient 
samples, GRHL2 is found to be downregulated in 
tumor cells compared normal tissue. Moreover, 
GRHL2 expression observed to be associated with 
higher chances for disease relapse (Butz et al,. 2014). 
Extending these observations on tumor-repressor 
properties of GRHL2, experimental studies showed 
that silencing of GRHL2 expression in a non-
tumorigenic kidney cell line results in an increased 
cell proliferation and increased resistance to 
apoptosis (Pawlak et al., 2017). 
Ovarian cancer 
The overexpressed GRHL2, due to 
hypomethylation, is observed to be significantly 
higher in low malignant potential (LMP) and high-
grade (HG) serous epithelial ovarian cancer (EOC) 
tumors compared with normal tissue.  Cell lines 
modelling EOC display an invasive and metastatic 
phenotype (Faddaoui et al., 2017). The oncogenic 
potential of GRHL2 is further suggested by the 
observations that the suppression of GRHL2 inhibits 
the proliferation, migration and invasion in ovarian 
cancer cell models (Chung et al., 2016). 
Colorectal cancer 
The expression of the GRHL2 is reported to be 
upregulated in colorectal cancer (CRC) samples 
compared to control non-tumorigenic tissue assessed 
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with immunohistochemistry, qRT-PCR, and western 
blot analyses. It appears that elevated levels of the 
GRHL2 expression are associated with tumor 
progression due to higher levels of cell proliferation. 
Consistent with these observations, the repression of 
GRHL2 synthesis decreases the proliferation by 
inhibiting cell cycle progression of CRC cell models 
and impairs tumor growth in a xenograft mouse 
model (Quan et al., 2014). 
Cervical cancer 
Analyses of cervical lesions of cancer patients 
indicate that the GRHL2 expression is diminished at 
both mRNA and protein level compared with normal 
tissue, which is also consistent with the expression 
analyses of cell lines derived from cervical cancer 
(Reyes et al., 2014). 
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